Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and lenvatinib with chemoradiotherapy for high-risk locally advanced cervical cancer
NL-OMON59887Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in Cervical Cancer (CC), sponsored by Erasmus MC. Primary endpoint: Progression-free survival at 24 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON59887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59887.